Merck spends $10 billion for Verona, gaining access to its COPD medication
With the acquisition, Merck gets access to Verona Pharma's chronic obstructive pulmonary disease medication Ohtuvayre. The Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of COPD in adults.
'Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders," Merck Chairman and CEO Robert Davis said in a statement.
"We believe Merck's commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD," Verona Pharma President and CEO David Zaccardelli said.
The deal, which was approved by the boards of both companies, is expected to close in the fourth quarter. It still needs approval of Verona Pharma shareholders and sanction by the High Court of Justice of England and Wales.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Is Wall Street Bullish or Bearish on Merck Stock?
Valued at $199.1 billion by market cap, Merck & Co., Inc. (MRK) is a leading American biopharmaceutical company based in Rahway, New Jersey. With a strong global presence, Merck develops prescription medicines, vaccines, biologic therapies, and animal health products, chiefly across oncology, immunology, infectious disease, and cardio-metabolic areas. Shares of Merck have slid 30.3% over the past year, significantly lagging behind the S&P 500 Index's ($SPX) 14.5% rise. This downward trend has persisted into 2025, with MRK down 20.3% year-to-date, in sharp contrast to the S&P 500's 6.1% gain. More News from Barchart Find Winning Momentum Trades With This Moving Average Stock Screener Tariffs, Earnings and Other Can't Miss Items this Week This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! MRK has also trailed the iShares U.S. Pharmaceuticals ETF (IHE), which is down 3.4% over the past year and has posted a modest 1.6% gain so far in 2025. On Jul. 29, Merck released its Q2 2025 results, with revenue dipping 2% year-over-year to $15.8 billion, missing analyst expectations, while adjusted EPS beat estimates at $2.13. Keytruda sales remained strong, rising 9% to around $8 billion, but this was offset by a steep 55% decline in Gardasil revenue due to weak demand in China and other international markets. As a result, its shares dipped 1.7% post earnings release. For fiscal 2025, ending in December 2025, analysts expected MRK's EPS to grow 17% to $8.95 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 24 analysts covering MRK stock, the consensus is a 'Moderate Buy.' The current consensus is based on 12 'Strong Buys' one 'Moderate Buy,' and 11 'Hold' ratings. This configuration is less bullish than two months ago, with 13 analysts suggesting a 'Strong Buy.' On July 30, Wells Fargo & Company (WFC) analyst Mohit Bansal maintained an "Equal-Weight" rating on Merck but lowered the price target from $97 to $90, reflecting a 7.2% downward revision despite no change in the overall rating. The mean price target of $102.05 represents a 28.7% premium to MRK's current price levels. The Street-high price target of $141 suggests an ambitious upside potential of 77.8%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
7 hours ago
- Yahoo
Pfizer (PFE) Reports Earnings Tomorrow: What To Expect
Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here's what to look for. Pfizer missed analysts' revenue expectations by 1.6% last quarter, reporting revenues of $13.72 billion, down 7.8% year on year. It was a mixed quarter for the company, with a solid beat of analysts' organic revenue estimates but a miss of analysts' full-year EPS guidance estimates. Is Pfizer a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Pfizer's revenue to grow 2.2% year on year to $13.58 billion, in line with the 2.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.57 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 6 downward revisions over the last 30 days (we track 11 analysts). Pfizer has missed Wall Street's revenue estimates three times over the last two years. Looking at Pfizer's peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts' expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%. Read our full analysis of Bristol-Myers Squibb's results here and Merck's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Pfizer is down 6.8% during the same time and is heading into earnings with an average analyst price target of $28.67 (compared to the current share price of $23.53). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
9 hours ago
- Yahoo
Amneal Earnings: What To Look For From AMRX
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here's what investors should know. Amneal missed analysts' revenue expectations by 3.4% last quarter, reporting revenues of $695.4 million, up 5.5% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Is Amneal a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Amneal's revenue to grow 5.8% year on year to $742.8 million, slowing from the 17.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amneal has missed Wall Street's revenue estimates three times over the last two years. Looking at Amneal's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts' expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%. Read our full analysis of Bristol-Myers Squibb's results here and Merck's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Amneal is down 5.1% during the same time and is heading into earnings with an average analyst price target of $11.75 (compared to the current share price of $7.98). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
